Recent Finacing
Recent Raise
Avraham Pharmaceuticals develops ladostigil— a cholinesterase and brain‑selective monoamine oxidase inhibitor licensed from Yissum and the Technion—and conducts multicenter randomized double‑blind placebo‑controlled Phase II trials for MCI and Alzheimer's
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors